怀孕相关的癌症:系统性审查和元分析
Ben Walters1, India Midwinter1, Carolyn A Chew-Graham2
1Academic Department of Obstetrics and Gynaecology, Royal Stoke Hospital, Stoke-on-Trent, United Kingdom.
Mayo Clinic proceedings. Innovations, quality & outcomes
|March 25, 2024
概括
怀孕相关癌症 (PAC) 显著增加了母亲和新生儿的风险,包括静脉血栓栓塞的7倍增加和42倍增加的孕产妇死亡率. 需要进一步的研究来了解这些风险.
科学领域:
- 产科和妇科 产科和妇科
- 在瘤学瘤学.
- 围产儿医学 围产儿医学
背景情况:
- 怀孕相关癌症 (PAC) 对母亲和新生儿健康构成了独特的挑战.
- 现有的有关PAC相关风险的数据是分散的,需要进行全面的评估.
研究的目的:
- 系统地评估和量化怀孕相关癌症 (PAC) 患者对孕妇和新生儿不良结果的风险.
- 通过元分析,提供与PAC相关的风险的定量综合.
主要方法:
- 在主要的生物医学数据库 (MEDLINE,Embase,Web of Science,Cochrane) 进行了系统的搜索.
- 来自22项研究的数据,包括59,190个PAC怀孕,被纳入随机效应元分析.
- 两个独立的审查员进行了研究选择,数据提取和质量评估.
主要成果:
- 患有PAC的妇女面临着剖腹产 (RR, 1.58),早产 (RR, 3.07),静脉血栓栓塞 (RR, 6.76) 和孕产妇死亡 (RR, 41.58) 的显着增加的风险.
- 只有对于仪器传递方式 (RR,0.67) 观察到风险降低.
- PAC与严重不良结果的大幅增加有关,包括VTE风险增加7倍和产妇死亡风险增加42倍.
结论:
- 怀孕相关的癌症与显著增加母亲和新生儿不良后果的风险有关.
- 患有PAC的妇女需要咨询,以了解她们的风险增加,特别是静脉血栓塞栓症和产妇死亡率.
- 进一步的研究对于阐明这些不良结果背后的机制至关重要,特别是对于产后诊断.
相关概念视频
Cancer Prevention
6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.2K
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Hazard Ratio
118
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
118
Teratogenicity
2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Disorders of the Female Reproductive System
357
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
357


